Low-dose IL-2 in Established T1D – The “PROREG” Study

Low-dose IL-2 in Established T1D – The “PROREG” Study

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes, Autoimmune
Interventions: Biological: ILT-101 (Aldesleukin; IL-2); Other: Treatment-Placebo Arm; Other: Placebo Arm
Sponsors: Jay S. Skyler; Diabetes Research Institute Foundation; University of Florida; University of California, San Francisco
Withdrawn

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 19, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments